Further support comes from the evidence of the effectiveness of anti-B cell therapeutic approach: in vivo, the inhibition of CD19 has been shown not only to abrogate autoantibody production but also to ameliorate skin fibrosis; SSc patients, particularly those ATA-positive, benefit from rituximab treatment [29]. Here, CD19 is linked to systemic sclerosis.